Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients
NCT06751992
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The objective of this randomized controlled study is to assess the neurocognitive outcomes between individuals using immediate-release (IR) tacrolimus (Prograf®) and those who were converted to extended-release tacrolimus (Envarsus XR) among older kidney transplant recipients (KTRs).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Kidney Transplant Recipients
- Old Age
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Massachusetts General Hospital
- Last updated on ClinicalTrials.gov
- May 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- MGH Kidney Transplant Clinic · Boston, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.